{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023518","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.503503+00:00","generated_at":"2026-06-22T01:53:02.934818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vera Therapeutics Q3 net loss $24.7M; cash $114.4M; atacicept Ph2b ORIGIN data early Q1 2023","bullets":["Net loss of $24.7M ($0.91 per share) vs $7.6M loss YoY; cash burn $46.4M YTD.","Cash, equivalents, and marketable securities $114.4M; additional $20M drawn from credit facility in Nov 2022; funds operations to Q2 2024.","Phase 2b ORIGIN trial of atacicept in IgA nephropathy topline data expected early Q1 2023.","Initiated pivotal Phase 3 COMPASS trial of atacicept in lupus nephritis.","Positive Phase 2 MAU868 results in BK viremia presented; plan to start Ph2b/Ph3 trial in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023518","json":"https://secwatch.observer/filing/0000950170-22-023518.json","markdown":"https://secwatch.observer/filing/0000950170-22-023518.md","text":"https://secwatch.observer/filing/0000950170-22-023518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/0000950170-22-023518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/vera-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:53:02.934818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c59ab4be01f9a2c36dd5aa9afee40cb7baec4da4","claim":"Vera Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income a net loss of $24.7 million, or a net loss per diluted share of $0.91, EPS $0.91.","evidence_excerpt":"For the three months ended September 30, 2022, the company reported a net loss of $24.7 million, or a net loss per diluted share of $0.91, compared to a net loss of $7.6 million, or a net loss per diluted share of $0.36, for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/0000950170-22-023518-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"a net loss of $24.7 million, or a net loss per diluted share of $0.91"},{"label":"EPS","value":"$0.91"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}